Key Takeaways
- A new initiative in Europe aims to improve understanding of whether digitization and decentralized clinical drug trials produce a smaller carbon footprint than traditional methods.
- The finding will helps sponsors and CROs adapt their processes to become more sustainable.
- Introducing more sustainable approaches to clinical research could help companies meet future carbon reduction demands from HTA bodies.
As pressure on the pharmaceutical industry to reduce its environmental impact grows, a new European initiative could help drug developers understand whether digital trial delivery methods and decentralized clinical trials...
The initiative was launched this month by the Pistoia Alliance, a non-profit organization that advocates for greater collaboration in life sciences R&D. Its portfolio lead, Thierry Escudier, explained to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?